Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Depreciation & Amortization (CF) (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $39000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 4.88% to $39000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $159000.0, a 8.16% increase, with the full-year FY2024 number at $143000.0, down 16.37% from a year prior.
  • Depreciation & Amortization (CF) was $39000.0 for Q3 2025 at Mereo BioPharma, down from $44000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $58000.0 in Q2 2023 to a low of $23000.0 in Q2 2024.
  • A 3-year average of $39545.5 and a median of $41000.0 in 2024 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): tumbled 60.34% in 2024, then surged 91.3% in 2025.
  • Mereo BioPharma's Depreciation & Amortization (CF) stood at $42000.0 in 2023, then fell by 9.52% to $38000.0 in 2024, then grew by 2.63% to $39000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Depreciation & Amortization (CF) are $39000.0 (Q3 2025), $44000.0 (Q2 2025), and $38000.0 (Q1 2025).